Cargando…
By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection
In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This appro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995085/ https://www.ncbi.nlm.nih.gov/pubmed/20846958 http://dx.doi.org/10.1093/nar/gkq789 |
_version_ | 1782193047214227456 |
---|---|
author | Ravn, U. Gueneau, F. Baerlocher, L. Osteras, M. Desmurs, M. Malinge, P. Magistrelli, G. Farinelli, L. Kosco-Vilbois, M.H. Fischer, N. |
author_facet | Ravn, U. Gueneau, F. Baerlocher, L. Osteras, M. Desmurs, M. Malinge, P. Magistrelli, G. Farinelli, L. Kosco-Vilbois, M.H. Fischer, N. |
author_sort | Ravn, U. |
collection | PubMed |
description | In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This approach allowed for in depth analysis of the library’s diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires. |
format | Text |
id | pubmed-2995085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-29950852010-12-01 By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection Ravn, U. Gueneau, F. Baerlocher, L. Osteras, M. Desmurs, M. Malinge, P. Magistrelli, G. Farinelli, L. Kosco-Vilbois, M.H. Fischer, N. Nucleic Acids Res Methods Online In recent years, unprecedented DNA sequencing capacity provided by next generation sequencing (NGS) has revolutionized genomic research. Combining the Illumina sequencing platform and a scFv library designed to confine diversity to both CDR3, >1.9 × 10(7) sequences have been generated. This approach allowed for in depth analysis of the library’s diversity, provided sequence information on virtually all scFv during selection for binding to two targets and a global view of these enrichment processes. Using the most frequent heavy chain CDR3 sequences, primers were designed to rescue scFv from the third selection round. Identification, based on sequence frequency, retrieved the most potent scFv and valuable candidates that were missed using classical in vitro screening. Thus, by combining NGS with display technologies, laborious and time consuming upfront screening can be by-passed or complemented and valuable insights into the selection process can be obtained to improve library design and understanding of antibody repertoires. Oxford University Press 2010-11 2010-09-15 /pmc/articles/PMC2995085/ /pubmed/20846958 http://dx.doi.org/10.1093/nar/gkq789 Text en © The Author(s) 2010. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/2.5 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Methods Online Ravn, U. Gueneau, F. Baerlocher, L. Osteras, M. Desmurs, M. Malinge, P. Magistrelli, G. Farinelli, L. Kosco-Vilbois, M.H. Fischer, N. By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title | By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title_full | By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title_fullStr | By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title_full_unstemmed | By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title_short | By-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
title_sort | by-passing in vitro screening—next generation sequencing technologies applied to antibody display and in silico candidate selection |
topic | Methods Online |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995085/ https://www.ncbi.nlm.nih.gov/pubmed/20846958 http://dx.doi.org/10.1093/nar/gkq789 |
work_keys_str_mv | AT ravnu bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT gueneauf bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT baerlocherl bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT osterasm bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT desmursm bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT malingep bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT magistrellig bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT farinellil bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT koscovilboismh bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection AT fischern bypassinginvitroscreeningnextgenerationsequencingtechnologiesappliedtoantibodydisplayandinsilicocandidateselection |